🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT07355920
Active, not recruiting Not applicable

Use of Alkasite for Postpulpotomy Restoration

NCT07355920 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2024-08-30
Last updated
2026-01-23

Condition(s) studied

Pediatric DentistryPost Pulpotomy Restoration

Investigational drug(s) / intervention(s)

Cention ForteTetric® N-Ceram

Cention Forte: 25 primary molars were restored with an Alkasite composite Cention-forte after Formocresol pulpotomy.

Tetric® N-Ceram: 5 primary molars were restored with Tetric® N-Ceram bulk-fill composite after Formocresol pulpotomy.

Study summary

The aim of this study will be directed to:

Evaluate the clinical performance of alkasite composite as a final restoration for pulpotomized primary molars.

Eligibility

Sex
ALL
Min age
4 Years
Max age
8 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Deep carious vital primary molars at site 1, 2, and size 3 according to the SI/STA classification of caries. * Healthy children free from systemic diseases. * Cooperative patient: Frankel rating 3,4. Radiographically: * Deep caries approximating the pulp. * Roots with no more than one-third physiologic resorption. * Normal lamina dura and periodontal ligament space. Exclusion Criteria: * Patients with bruxism. * Clinical signs or symptoms of irreversible pulpitis or pulp degeneration. * Parents refuse treatment. Radiographically: * Furcation involvement. * periapical lesion. * Pathologic resorption (internal or external).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The clinical study was carried out at the clinic of Pediatric and Preventive Dentistry Department, Faculty of dentistry, Tanta university. Tanta Egypt

More Tanta University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07355920 on ClinicalTrials.gov ↗ ← All trials in Egypt